MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
OLMA - Olema Pharmaceuticals Inc
$37.66
1.25(3.43%)9:00:00 PM 3/5/2021
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Stock news

    02/23/2021OLMA
    Olema Oncology to Participate at Upcoming Virtual Investor Conferences

    SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will participate at the following upcoming virtual investor conferences: Cowen 41st Annual Health Care ConferenceDate and Time: March 2, 2021 at 2:10 p.m. Eastern TimeSean P. Bohen, M.D., Ph.D., President and...

    02/19/2021OLMA
    We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash Wisely

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

    12/31/2020OLMA
    Biotech IPO Frenzy Brings in 3 Stocks to Buy

    2020 was a year to remember, for so many reasons, but there is one reason that might not be obvious: it was the year of the IPO. The crazy corona crisis year didn’t just bring us social distancing and mass mask mandates, it also brought us a huge number of IPOs, with well over 200 companies entering the public realm – that’s 34% more than 2019, and the most since 2014.And, it was the year of unicorn, too. Unicorns, or billion-dollar start-ups, were more common than usual in the IPO ranks. The ag...

    12/17/2020OLMA
    Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

    SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., president and chief executive officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 10 a.m. Eastern Time. The presentatio...

    12/7/2020OLMA
    Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020

    SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-1...

    12/3/2020OLMA
    Kinnate Biopharma Stock Nearly Doubles in Debut. More Deals Are Coming.

    Shares of Kinnate Biopharma opened at $40, double the initial public offering price, and ended the day up 95%.

    11/23/2020OLMA
    Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additi...

    11/20/2020OLMA
    Maravai LifeSciences Jumps Nearly 19% in IPO, While Sotera Pops 17%

    Both companies are backed by GTCR, the Chicago buyout shop. IPOs came back this week following a pause for the presidential election.

    11/19/2020OLMA
    IPOs Are Back After Election Pause. Olema Pharmaceuticals Stock Jumped 158%.

    Olema Pharmaceuticals, NeoGames, Yatsen Holding and Telos made their market debuts Thursday. The traditional IPOs are the first to trade since Nov. 3.